CSPC Pharma Gains NMPA Clearance for New-Generation Aprepitant Injection Targeting Post-Operative Nausea

Bulletin Express

Yesterday

CSPC Pharmaceutical Group Limited (CSPC Pharma) has obtained drug-registration approval from China’s National Medical Products Administration (NMPA) for its Aprepitant Injection (4.4 ml:32 mg), a submicron emulsion formulation of the neurokinin-1 (NK-1) receptor antagonist aprepitant.

The newly approved product is indicated for the prevention of post-operative nausea and vomiting (PONV) in adults. According to the company, the submicron emulsion offers a faster onset of action, improves patient compliance and lowers the incidence of allergic reactions compared with traditional aprepitant formulations, potentially enhancing clinical outcomes in surgical aftercare.

This approval follows the September 2024 clearance of CSPC Pharma’s Aprepitant Injection (18 ml:130 mg), which is used to prevent chemotherapy-induced nausea and vomiting. The addition of the 32 mg dosage form broadens the company’s antiemetic portfolio and strengthens its competitive position in this therapeutic segment.

The announcement was issued by CSPC Pharma’s board on 23 March 2026. Chairman: Cai Dong Chen.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1116677199"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116677199\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116677199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116677199","market":"us","top_or_hot":-1,"title":"CSPC Pharma Gains NMPA Clearance for New-Generation Aprepitant Injection Targeting Post-Operative Nausea","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has obtained drug-registration approval from China’s National Medical Products Administration (NMPA) for its Aprepitant Injection (4.4 ml:32 mg), a submicron emulsion formulation of the neurokinin-1 (NK-1) receptor antagonist aprepitant.</p>\n<p>The newly approved product is indicated for the prevention of post-operative nausea and vomiting (PONV) in adults. According to the company, the submicron emulsion offers a faster onset of action, improves patient compliance and lowers the incidence of allergic reactions compared with traditional aprepitant formulations, potentially enhancing clinical outcomes in surgical aftercare.</p>\n<p>This approval follows the September 2024 clearance of CSPC Pharma’s Aprepitant Injection (18 ml:130 mg), which is used to prevent chemotherapy-induced nausea and vomiting. The addition of the 32 mg dosage form broadens the company’s antiemetic portfolio and strengthens its competitive position in this therapeutic segment.</p>\n<p>The announcement was issued by CSPC Pharma’s board on 23 March 2026. Chairman: Cai Dong Chen.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Gains NMPA Clearance for New-Generation Aprepitant Injection Targeting Post-Operative Nausea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Gains NMPA Clearance for New-Generation Aprepitant Injection Targeting Post-Operative Nausea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-23 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has obtained drug-registration approval from China’s National Medical Products Administration (NMPA) for its Aprepitant Injection (4.4 ml:32 mg), a submicron emulsion formulation of the neurokinin-1 (NK-1) receptor antagonist aprepitant.</p>\n<p>The newly approved product is indicated for the prevention of post-operative nausea and vomiting (PONV) in adults. According to the company, the submicron emulsion offers a faster onset of action, improves patient compliance and lowers the incidence of allergic reactions compared with traditional aprepitant formulations, potentially enhancing clinical outcomes in surgical aftercare.</p>\n<p>This approval follows the September 2024 clearance of CSPC Pharma’s Aprepitant Injection (18 ml:130 mg), which is used to prevent chemotherapy-induced nausea and vomiting. The addition of the 32 mg dosage form broadens the company’s antiemetic portfolio and strengthens its competitive position in this therapeutic segment.</p>\n<p>The announcement was issued by CSPC Pharma’s board on 23 March 2026. Chairman: Cai Dong Chen.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1116677199","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116677199","pubTimestamp":1774263802,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has obtained drug-registration approval from China’s National Medical Products Administration (NMPA) for its Aprepitant Injection (4.4 ml:32 mg), a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团针对术后恶心的新一代阿瑞匹坦注射液获NMPA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has obtained drug-registration approval from China’s National Medical Products Administration (NMPA) for its Aprepitant Injection (4.4 ml:32 mg), a submicron emulsion formulation of the neurokinin-1 (NK-1) receptor antagonist aprepitant.\nThe newly approved product is indicated for the prevention of post-operative nausea and vomiting (PONV) in adults. According to the company, the submicron emulsion offers a faster onset of action, improves patient compliance and lowers the incidence of allergic reactions compared with traditional aprepitant formulations, potentially enhancing clinical outcomes in surgical aftercare.\nThis approval follows the September 2024 clearance of CSPC Pharma’s Aprepitant Injection (18 ml:130 mg), which is used to prevent chemotherapy-induced nausea and vomiting. The addition of the 32 mg dosage form broadens the company’s antiemetic portfolio and strengthens its competitive position in this therapeutic segment.\nThe announcement was issued by CSPC Pharma’s board on 23 March 2026. Chairman: Cai Dong Chen.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}